Karyopharm Therapeutics Inc. (NASDAQ:KPTI) fell 1.9% during trading on Wednesday . The company traded as low as $6.77 and last traded at $6.85, with a volume of 148,712 shares changing hands. The stock had previously closed at $6.98.

A number of research firms recently commented on KPTI. Leerink Swann reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Sunday, June 12th. Zacks Investment Research downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. Robert W. Baird began coverage on Karyopharm Therapeutics in a report on Monday, June 27th. They issued an “outperform” rating and a $16.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday. Finally, Raymond James Financial Inc. began coverage on Karyopharm Therapeutics in a report on Friday, May 27th. They issued an “outperform” rating and a $13.00 price objective for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.50.

The stock’s market capitalization is $254.24 million. The firm has a 50-day moving average of $7.29 and a 200-day moving average of $7.78.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. Equities analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.09) EPS for the current fiscal year.

In related news, major shareholder Ltd Chione sold 93,932 shares of the firm’s stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $8.54, for a total transaction of $802,179.28. Following the sale, the insider now owns 8,873,932 shares of the company’s stock, valued at approximately $75,783,379.28. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

An institutional investor recently raised its position in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC increased its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned about 0.25% of Karyopharm Therapeutics worth $1,167,000 as of its most recent filing with the SEC.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.